{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:04:28Z","timestamp":1781197468394,"version":"3.54.1"},"reference-count":16,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In patients presenting with inflammatory bowel disease (IBD), it may not be possible to diagnose ulcerative colitis (UC) or Crohn\u2019s disease (CD) and a classification of IBD Unclassified (IBD-U) is applied. We aim to describe the long-term natural history and treatment patterns in IBD-U.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis was based on the Leeds IBD Steroid Study, a large retrospective study conducted at Leeds Teaching Hospitals (a UK-based tertiary IBD unit) that included all adult patients with an established diagnosis of IBD who had contact with the service between January 2016 and December 2017 and where access to primary care records were linked to hospital electronic records. Patients with IBD-U were analysed retrospectively. Baseline demographics and treatment patterns of patients with IBD-U were compared with UC and CD. Longitudinal follow-up occurred until 2025 to determine stability of IBD-U diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 153 patients with IBD-U, 52% were male; the mean age was 46.6 years, and the mean disease duration was 13.1 years. Patients with IBD-U were less likely to receive mesalazine (85%) compared with UC (92%, p=0.0058) but more likely than patients with CD (44%, p&lt;0.0001). Biologics were more often used for IBD-U (21%) than UC (9.5%, p&lt;0.0001) but less often than CD (51%, p&lt;0.0001). Steroid use and use of healthcare resources were higher in IBD-U than in UC and CD. 12 patients (7.8%) were reclassified as UC, 6 patients (3.9%) were reclassified as CD and 135 patients (88.2%) remained classified as IBD-U at the end of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IBD-U remains largely a stable diagnosis over long-term follow-up. Patients with IBD-U exhibit distinct therapeutic patterns and increased healthcare utilisation compared with UC and CD. These findings underscore the clinical relevance of IBD-U as a persistent phenotype and highlight the need to optimise treatment decisions and reduce the burden associated with diagnostic uncertainty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2026-002339","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:35:18Z","timestamp":1781195718000},"page":"e002339","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term classification stability and treatment patterns of inflammatory bowel disease unclassified: a longitudinal observational study"],"prefix":"10.1136","volume":"13","author":[{"given":"Mario Andrea","family":"Latorre","sequence":"first","affiliation":[{"name":"Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rennie","sequence":"additional","affiliation":[{"name":"Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7260-1866","authenticated-orcid":false,"given":"Konstantina","family":"Rosiou","sequence":"additional","affiliation":[{"name":"Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Vincenzo","family":"Lenti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy"},{"name":"First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-5859","authenticated-orcid":false,"given":"Christian Philipp","family":"Selinger","sequence":"additional","affiliation":[{"name":"Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026061109351146000_13.1.e002339.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2002697"},{"key":"2026061109351146000_13.1.e002339.2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020305","article-title":"Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases","volume":"13","author":"Calvez","year":"2025","journal-title":"Biomedicines"},{"key":"2026061109351146000_13.1.e002339.3","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf106","article-title":"ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1","volume":"19","author":"Kucharzik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026061109351146000_13.1.e002339.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334395"},{"key":"2026061109351146000_13.1.e002339.5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ecco-jcc\/jjab141","article-title":"ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease","volume":"16","author":"Feakins","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026061109351146000_13.1.e002339.6","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200309000-00007"},{"key":"2026061109351146000_13.1.e002339.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318936"},{"key":"2026061109351146000_13.1.e002339.8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/jgh.14563","article-title":"Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study","volume":"34","author":"Burisch","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2026061109351146000_13.1.e002339.9","doi-asserted-by":"crossref","first-page":"i2275","DOI":"10.1093\/ecco-jcc\/jjae190.1432","article-title":"P1258 Disease course of inflammatory bowel disease unclassified during the first ten years following diagnosis: A prospective European population-based inception cohort \u2013 the Epi-IBD cohort","volume":"19","author":"Wewer","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026061109351146000_13.1.e002339.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-024-03171-5","article-title":"Clinical features of inflammatory bowel disease unclassified: a case-control study","volume":"24","author":"Shao","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"2026061109351146000_13.1.e002339.11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/apt.17039","article-title":"Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study","volume":"56","author":"Rosiou","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061109351146000_13.1.e002339.12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad203"},{"key":"2026061109351146000_13.1.e002339.13","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otac041","article-title":"The Use and Efficacy of Biological Therapies for Inflammatory Bowel Disease in a Danish Tertiary Centre 2010-2020","volume":"4","author":"Wewer","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026061109351146000_13.1.e002339.14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/apt.14334","article-title":"A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease","volume":"46","author":"Selinger","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061109351146000_13.1.e002339.15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.15497","article-title":"Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients","volume":"50","author":"Selinger","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061109351146000_13.1.e002339.16","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102409"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:35:20Z","timestamp":1781195720000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjgast-2026-002339"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002339","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}